Experiment 1054776

Worktypes

ANTICANCER AND/OR CYTOTOXICITY MARKER CODEPHARMACOLOGY OF COMPOUND - IN HUMANS

Compounds isolated

CARMINOMYCIN

Alerts

DOSING ON DAYS 1-5.DATA INCOMPLETE - DERIVED FROM AN ABSTRACT.

Details

PropertyValue
Pharmacology
ANTITUMOR ACTIVITY
Administration routeIV BOLUS
OrganismEmpty organism
CitationDEBUSSCHER,S: MALARME,D: BRON,D: VAN RIJMENANT,M: ROZENCWEIG,M: STRYCKMANS,P:. (1984). PHASE I-II EVALUATION OF CARMINOMYCIN (CMM) IN ADULTS WITH ACUTE LEUKEMIA.. ()
Amount utilized
Compound isolated
DiseasePHASE I-II TRIAL ON PATIENTS WITH LEUKEMIA. 4 REMISSIONS AT HIGHER DOSE LEVELS. SEVERE MYELOSUPRESSION IN ALL PAITENTS.MUCOSITIS WAS DOSE-DEPENDENT.FATALITY OF NECROSIS OF THE GUT AT HIGHEST DOSE LEVELS.GIVEN TO 19 PATIENTS.
Dose amount6-14 MG
Number1
Qualitative result.
AnimalHUMAN ADULT
Per unitSQ M BODY SURFACE
Dose expressionDOSE